{"id":61459,"date":"2025-06-20T16:03:45","date_gmt":"2025-06-20T14:03:45","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/"},"modified":"2025-06-20T16:03:45","modified_gmt":"2025-06-20T14:03:45","slug":"cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/","title":{"rendered":"Cancer Diagnostic Collaboration, R&amp;D, and Licensing Deals Analysis Report 2025: Access 724 Deals Signed Since 2018 &#8211; Upfront, Milestone, Royalties Financial Terms, Company, Deal Type and Therapy Area &#8211; ResearchAndMarkets.com"},"content":{"rendered":"<div>\n<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/3292770\/cancer-diagnostic-collaboration-and-licensing?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=rck6n4&amp;utm_campaign=2071119+-+Cancer+Diagnostic+Collaboration%2C+R%26D%2C+and+Licensing+Deals+Analysis+Report+2025%3A+Access+724+Deals+Signed+Since+2018+-+Upfront%2C+Milestone%2C+Royalties+Financial+Terms%2C+Company%2C+Deal+Type+and+Therapy+Area&amp;utm_exec=chdomspi\" rel=\"nofollow\" shape=\"rect\">&#8220;Cancer Diagnostic Collaboration and Licensing Deals 2018-2025&#8221;<\/a> report has been added to <strong>ResearchAndMarkets.com&#8217;s<\/strong> offering.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250620154217\/en\/2503279\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250620154217\/en\/2503279\/22\/logo.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250620154217\/en\/2503279\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250620154217\/en\/2503279\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThis report contains a comprehensive listing of 724 cancer diagnostic deals announced since 2018 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.<\/p>\n<p>\nFully revised and updated, the report provides details of cancer diagnostic deals from 2018 to 2025. The report provides a detailed understanding and analysis of how and why companies enter cancer diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes. Cancer Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer diagnostic deals entered into by the world&#8217;s leading biopharma companies.<\/p>\n<p>\nThe initial chapters of this report provide an orientation of cancer diagnostic dealmaking.<\/p>\n<p>\nChapter 1 provides an introduction to the report.<\/p>\n<p>\nChapter 2 provides an overview of the trends in cancer diagnostic dealmaking since 2018.<\/p>\n<p>\nChapter 3 provides an overview of the leading cancer diagnostic deals since 2018. Deals are listed by headline value.<\/p>\n<p>\nChapter 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostic dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostic deals, as well as contract documents available in the public domain.<\/p>\n<p>\nChapter 5 provides a comprehensive and detailed review of cancer diagnostic deals signed and announced since Jan 2018, where a contract document is available in the public domain.<\/p>\n<p>\nChapter 6 provides a comprehensive and detailed review of cancer diagnostic partnering deals signed and announced since Jan 2018. The chapter is organized by specific cancer diagnostic technology type in focus.<\/p>\n<p>\nThe report also includes numerous table and figures that illustrate the trends and activities in cancer diagnostic deal making since 2018.<\/p>\n<p>\nIn addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.<\/p>\n<p>\n<strong>Cancer Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:<\/strong><\/p>\n<ul>\n<li>\nUnderstand deal trends since 2018<\/li>\n<li>\nBrowse cancer diagnostic collaboration and licensing deals<\/li>\n<li>\nBenchmark analysis &#8211; identify market value of transactions<\/li>\n<li>\nFinancials terms &#8211; upfront, milestone, royalties<\/li>\n<li>\nDirectory of deals by company A-Z, deal type and therapy area<\/li>\n<li>\nLeading deals by value<\/li>\n<li>\nMost active dealmakers<\/li>\n<li>\nIdentify assets and deal terms for each transaction<\/li>\n<li>\nAccess contract documents &#8211; insights into deal structures<\/li>\n<li>\nDue diligence &#8211; assess suitability of your proposed deal terms for partner companies<\/li>\n<li>\nSave hundreds of hours of research time<\/li>\n<\/ul>\n<p>\n<strong>Cancer Diagnostic Collaboration and Licensing Deals includes:<\/strong><\/p>\n<ul>\n<li>\nTrends in cancer diagnostic dealmaking in the biopharma industry<\/li>\n<li>\nDirectory of cancer diagnostic deal records covering pharmaceutical and biotechnology<\/li>\n<li>\nThe leading cancer diagnostic deals by value<\/li>\n<li>\nMost active cancer diagnostic licensing dealmakers<\/li>\n<\/ul>\n<p>\n<strong>Analyzing contract agreements allows due diligence of:<\/strong><\/p>\n<ul>\n<li>\nWhat are the precise rights granted or optioned?<\/li>\n<li>\nWhat is actually granted by the agreement to the partner company?<\/li>\n<li>\nWhat exclusivity is granted?<\/li>\n<li>\nWhat is the payment structure for the deal?<\/li>\n<li>\nHow are sales and payments audited?<\/li>\n<li>\nWhat is the deal term?<\/li>\n<li>\nHow are the key terms of the agreement defined?<\/li>\n<li>\nHow are IPRs handled and owned?<\/li>\n<li>\nWho is responsible for commercialization?<\/li>\n<li>\nWho is responsible for development, supply, and manufacture?<\/li>\n<li>\nHow is confidentiality and publication managed?<\/li>\n<li>\nHow are disputes to be resolved?<\/li>\n<li>\nUnder what conditions can the deal be terminated?<\/li>\n<li>\nWhat happens when there is a change of ownership?<\/li>\n<li>\nWhat sublicensing and subcontracting provisions have been agreed?<\/li>\n<li>\nWhich boilerplate clauses does the company insist upon?<\/li>\n<li>\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?<\/li>\n<li>\nWhich jurisdiction does the company insist upon for agreement law?<\/li>\n<\/ul>\n<p>\n<strong>Key Topics Covered:<\/strong><\/p>\n<p>\n<strong>Executive Summary<\/strong><\/p>\n<p>\n<strong>Chapter 1 &#8211; Introduction<\/strong><\/p>\n<p>\n<strong>Chapter 2 &#8211; Trends in cancer diagnostic dealmaking<\/strong><\/p>\n<p>\n2.1. Introduction<\/p>\n<p>\n2.2. Cancer diagnostic deals over the years<\/p>\n<p>\n2.3. Most active cancer diagnostic dealmakers<\/p>\n<p>\n2.4. Cancer diagnostic deals by deal type<\/p>\n<p>\n2.5. Cancer diagnostic deals by therapy area<\/p>\n<p>\n2.6. Cancer diagnostic deals by industry sector<\/p>\n<p>\n2.7. Deal terms for cancer diagnostic deals<\/p>\n<p>\n2.7.1 Cancer diagnostic deals headline values<\/p>\n<p>\n2.7.2 Cancer diagnostic deal upfront payments<\/p>\n<p>\n2.7.3 Cancer diagnostic deal milestone payments<\/p>\n<p>\n2.7.4 Cancer diagnostic royalty rates<\/p>\n<p>\n<strong>Chapter 3 &#8211; Leading cancer diagnostic deals<\/strong><\/p>\n<p>\n3.1. Introduction<\/p>\n<p>\n3.2. Top cancer diagnostic deals by value<\/p>\n<p>\n<strong>Chapter 4 &#8211; Most active cancer diagnostic dealmakers<\/strong><\/p>\n<p>\n4.1. Introduction<\/p>\n<p>\n4.2. Most active cancer diagnostic dealmakers<\/p>\n<p>\n4.3. Most active cancer diagnostic deals company profiles<\/p>\n<p>\n<strong>Chapter 5 &#8211; Cancer diagnostic contracts dealmaking directory<\/strong><\/p>\n<p>\n5.1. Introduction<\/p>\n<p>\n5.2. Cancer diagnostic contracts dealmaking directory<\/p>\n<p>\n<strong>Chapter 6 &#8211; Cancer diagnostic dealmaking by technology type<\/strong><\/p>\n<p>\nFor more information about this report visit <a target=\"_blank\" href=\"https:\/\/www.researchandmarkets.com\/reports\/3292770\/cancer-diagnostic-collaboration-and-licensing?utm_source=BW&amp;utm_medium=PressRelease&amp;utm_code=rck6n4&amp;utm_campaign=2071119+-+Cancer+Diagnostic+Collaboration%2C+R%26D%2C+and+Licensing+Deals+Analysis+Report+2025%3A+Access+724+Deals+Signed+Since+2018+-+Upfront%2C+Milestone%2C+Royalties+Financial+Terms%2C+Company%2C+Deal+Type+and+Therapy+Area&amp;utm_exec=chdomspi\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.researchandmarkets.com\/r\/s6x20w<\/a><\/p>\n<p>\n<strong>About ResearchAndMarkets.com<\/strong><\/p>\n<p>\nResearchAndMarkets.com is the world&#8217;s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nResearchAndMarkets.com<br \/>\n<br \/>Laura Wood, Senior Press Manager<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x70;r&#x65;s&#x73;&#64;&#x72;e&#115;&#x65;&#97;&#x72;&#99;&#x68;&#97;&#x6e;&#100;&#x6d;a&#x72;k&#x65;t&#x73;&#46;&#99;&#x6f;&#109;\" rel=\"nofollow\" shape=\"rect\">&#112;r&#x65;s&#x73;&#64;&#x72;&#101;&#x73;&#101;&#x61;&#114;c&#x68;a&#x6e;d&#x6d;&#97;&#x72;&#107;&#x65;&#116;&#x73;&#46;c&#x6f;m<\/a><br \/>For E.S.T Office Hours Call 1-917-300-0470<br \/>\n<br \/>For U.S.\/ CAN Toll Free Call 1-800-526-8630<br \/>\n<br \/>For GMT Office Hours Call +353-1-416-8900<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cancer Diagnostic Collaboration and Licensing Deals 2018-2025&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report contains a comprehensive listing of 724 cancer diagnostic deals announced since 2018 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61459","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cancer Diagnostic Collaboration, R&amp;D, and Licensing Deals Analysis Report 2025: Access 724 Deals Signed Since 2018 - Upfront, Milestone, Royalties Financial Terms, Company, Deal Type and Therapy Area - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancer Diagnostic Collaboration, R&amp;D, and Licensing Deals Analysis Report 2025: Access 724 Deals Signed Since 2018 - Upfront, Milestone, Royalties Financial Terms, Company, Deal Type and Therapy Area - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cancer Diagnostic Collaboration and Licensing Deals 2018-2025&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report contains a comprehensive listing of 724 cancer diagnostic deals announced since 2018 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-20T14:03:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250620154217\/en\/2503279\/22\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cancer Diagnostic Collaboration, R&amp;D, and Licensing Deals Analysis Report 2025: Access 724 Deals Signed Since 2018 &#8211; Upfront, Milestone, Royalties Financial Terms, Company, Deal Type and Therapy Area &#8211; ResearchAndMarkets.com\",\"datePublished\":\"2025-06-20T14:03:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/\"},\"wordCount\":887,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250620154217\\\/en\\\/2503279\\\/22\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/\",\"name\":\"Cancer Diagnostic Collaboration, R&amp;D, and Licensing Deals Analysis Report 2025: Access 724 Deals Signed Since 2018 - Upfront, Milestone, Royalties Financial Terms, Company, Deal Type and Therapy Area - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250620154217\\\/en\\\/2503279\\\/22\\\/logo.jpg\",\"datePublished\":\"2025-06-20T14:03:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250620154217\\\/en\\\/2503279\\\/22\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250620154217\\\/en\\\/2503279\\\/22\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cancer Diagnostic Collaboration, R&amp;D, and Licensing Deals Analysis Report 2025: Access 724 Deals Signed Since 2018 &#8211; Upfront, Milestone, Royalties Financial Terms, Company, Deal Type and Therapy Area &#8211; ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cancer Diagnostic Collaboration, R&amp;D, and Licensing Deals Analysis Report 2025: Access 724 Deals Signed Since 2018 - Upfront, Milestone, Royalties Financial Terms, Company, Deal Type and Therapy Area - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/","og_locale":"en_US","og_type":"article","og_title":"Cancer Diagnostic Collaboration, R&amp;D, and Licensing Deals Analysis Report 2025: Access 724 Deals Signed Since 2018 - Upfront, Milestone, Royalties Financial Terms, Company, Deal Type and Therapy Area - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN&#8211;(BUSINESS WIRE)&#8211;The &#8220;Cancer Diagnostic Collaboration and Licensing Deals 2018-2025&#8221; report has been added to ResearchAndMarkets.com&#8217;s offering. This report contains a comprehensive listing of 724 cancer diagnostic deals announced since 2018 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/","og_site_name":"Pharma Trend","article_published_time":"2025-06-20T14:03:45+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250620154217\/en\/2503279\/22\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cancer Diagnostic Collaboration, R&amp;D, and Licensing Deals Analysis Report 2025: Access 724 Deals Signed Since 2018 &#8211; Upfront, Milestone, Royalties Financial Terms, Company, Deal Type and Therapy Area &#8211; ResearchAndMarkets.com","datePublished":"2025-06-20T14:03:45+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/"},"wordCount":887,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250620154217\/en\/2503279\/22\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/","url":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/","name":"Cancer Diagnostic Collaboration, R&amp;D, and Licensing Deals Analysis Report 2025: Access 724 Deals Signed Since 2018 - Upfront, Milestone, Royalties Financial Terms, Company, Deal Type and Therapy Area - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250620154217\/en\/2503279\/22\/logo.jpg","datePublished":"2025-06-20T14:03:45+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250620154217\/en\/2503279\/22\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250620154217\/en\/2503279\/22\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cancer-diagnostic-collaboration-rd-and-licensing-deals-analysis-report-2025-access-724-deals-signed-since-2018-upfront-milestone-royalties-financial-terms-company-deal-type-and-therapy-area\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cancer Diagnostic Collaboration, R&amp;D, and Licensing Deals Analysis Report 2025: Access 724 Deals Signed Since 2018 &#8211; Upfront, Milestone, Royalties Financial Terms, Company, Deal Type and Therapy Area &#8211; ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61459"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61459\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}